Evotec's Block Trade and Its Earnings Beat Tell Two Different Stories

Evotec investors have two pieces of news to weigh, and they pull in opposite directions. On one side sits a private block sale that removed a major shareholder from the register. On the other, preliminary nine-month figures that came in ahead of market expectations. Neither event, on its own, settles the question of whether the German drug developer's business is genuinely improving.

The ownership change came first. On 9 October, Ninety Fourth Investment Company sold 11,481,502 Evotec shares in a privately negotiated block transaction, with the announcement indicating the stake would be disposed of in full. The sale pushed Mubadala Investment Company, Mamoura Diversified Global Holding and Ninety Fourth Investment Company below the 5% shareholding threshold. That reshapes the shareholder base, but it says nothing directly about whether Evotec's operations are getting better or worse.

A beat that measures the gap, not the business

The preliminary numbers for the first nine months of 2026 showed group revenue of roughly EUR 465.0 million and an adjusted group EBITDA of about EUR –42.8 million. According to the company, both figures exceeded market expectations. Beating the consensus is a welcome signal, particularly when investors had been bracing for weaker results — but it measures the distance to the market's prior forecast, not profitability or a durable upturn.

The confirmed full-year outlook keeps that distinction front and centre. Evotec reiterated revenue of around EUR 570 million to EUR 610 million for 2026, alongside an adjusted group EBITDA of roughly EUR –70 million to EUR –105 million. In other words, the better-than-expected interim data did not come with a raised forecast. That doesn't erase the surprise, but it does cap how far investors should extrapolate it. On the adjusted earnings line, the year is still projected to close in the red.

Two analysts, two very different price targets

How optimistically the interim figures can be read was on display in mid-October. RBC Capital Markets reaffirmed its "Outperform" rating and a EUR 10 price target on 14 October, with analyst Charles Weston pointing to revenue and operating profit above expectations as well as the confirmed annual guidance. That is an optimistic reading of future possibilities, not a certainty — a price target is a valuation of what might be, and it should not carry more weight than the question of whether Evotec can demonstrably improve its economics.

Deutsche Bank Research supplied the counterweight. On Thursday, analyst Fynn Scherzler kept a "Hold" rating and a EUR 3.50 price target. Set beside RBC's far higher mark, the two calls lay bare just how wide the range of professional opinion has become. For holders, that spread is itself a valuation risk: a positive surprise can lose its force if the full numbers fail to justify stronger earnings confidence, and the block sale could then loom larger in the narrative. That is a possible scenario, not an operating trend already proven by the share disposal.

What the 5 November release has to deliver

The next hard catalyst is the full third-quarter and nine-month results, scheduled for 5 November 2026. That publication should turn the preliminary headline figures into a broader basis for judging how the business actually performed. Until then, the constructive case for operational stabilisation remains defensible only as long as the preliminary numbers and the annual guidance both hold. Should either be revised, that view would need revisiting too.

The sensible stance sits between blanket scepticism and premature confidence. Evotec has delivered a positive data point, and the beat deserves acknowledgement. But the larger task — turning that surprise into a convincing earnings trajectory — is still ahead. Ownership changes and operating progress are best judged separately, and on 5 November the company gets its chance to show which one deserves the greater weight.